Theravance Updates Guidance for Initiation of Phase 2b in the LABA Collaboration
Tuesday January 10, 7:30 pm ET
SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Jan 10, 2006 -- Theravance, Inc. (NasdaqNM:THRX - News) announced today that it expects GlaxoSmithKline, Inc. (GSK) to initiate a Phase 2b program with GSK159797 ('797), the lead investigational compound in the companies' Beyond Advair collaboration, during the first half of 2006. The Phase 2b program is designed to assess the safety and efficacy of '797 in multi-day administration to mild-to-moderate asthmatics and to assess potential commercial dosing.
'797 is a novel long acting beta-2 agonist (LABA) discovered by Theravance that is being developed as part of its Beyond Advair collaboration with GSK for the treatment of asthma and chronic obstructive pulmonary disease (COPD). In this collaboration, there are currently eight LABA candidates in the development pool, five of which are in or have completed Phase 2a studies. Previously presented data demonstrated that '797 is a potent beta-2 receptor agonist that provides 24 hour bronchodilation with minimal increases in heart rate.
Conference Call and Webcast Information
Theravance has scheduled a conference call to discuss this announcement Wednesday, January 11th beginning at 5:45 a.m. Pacific Standard Time. To participate in the live call by telephone, please dial 800-810-0924 from the U.S., or 913-981-4900 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's web site at www.theravance.com. To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.
A replay of the conference call will be available on the Company's web site for 30 days through February 10, 2006. An audio replay will also be available through 11:59 p.m. Eastern Standard Time on January 25, 2006 by dialing 888-203-1112 from the U.S., or 719-457-0820 for international callers, and entering confirmation code 9464041.
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Of the five programs in development, two are in late stage -- telavancin, and the Beyond Advair collaboration with GlaxoSmithKline. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal disorders. By leveraging its proprietary insight of multivalency to drug discovery focused on validated targets, Theravance is pursuing a next generation drug discovery strategy designed to discover superior medicines in large markets. For more information, please visit the company's web site at www.theravance.com. |
